Literature DB >> 2537257

Inhibition of Leishmania donovani promastigote internalization into murine macrophages by chemically defined parasite glycoconjugate ligands.

C B Palatnik1, R Borojevic, J O Previato, L Mendonça-Previato.   

Abstract

Leishmania donovani, the agent of human visceral leishmaniasis, is an intracellular parasite that must be recognized and internalized by host macrophages to complete its biological cycle. In a search for possible ligands for macrophage surface receptors, glycoconjugates were obtained from Leishmania promastigotes by aqueous, phenol-aqueous, and alkaline extraction. A fucose-mannose glycoproteic ligand, a lipopeptidephosphoglycan, and a phosphate mannogalactan ligand were purified from promastigotes and analyzed for their chemical contents, with special attention to their glycidic moieties. Sugars that were identified as components of these glycoconjugates were tested for their capacity to inhibit promastigote internalization by BALB/c peritoneal macrophages in vitro. Neutral hexoses showed little inhibitory activity; fucose, charged monosaccharides, and a mannose polymer showed the highest activity. Two of the glycoconjugates (fucose-mannose glycoproteic ligand and phosphate mannogalactan ligand) purified from promastigotes were potent inhibitors of internalization, 75% inhibition being obtained at concentrations of 6 to 10 micrograms/ml. The simultaneous presence of both ligands in low concentrations yielded an increase in inhibitory activity above that found for each ligand alone, indicating that promastigotes may use at least two receptor sites for penetration into macrophages. These ligands are specific inhibitors of L. donovani promastigote phagocytosis, since 10 micrograms of each ligand per ml interfered neither with internalization of yeast cells nor with phagocytosis of Leishmania adleri promastigotes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2537257      PMCID: PMC313173          DOI: 10.1128/iai.57.3.754-763.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  The glycoconjugate derived from a Leishmania major receptor for macrophages is a suppressogenic, disease-promoting antigen in murine cutaneous leishmaniasis.

Authors:  G F Mitchell; E Handman
Journal:  Parasite Immunol       Date:  1986-05       Impact factor: 2.280

2.  Expression of an unusual acidic glycoconjugate in Leishmania donovani.

Authors:  S J Turco; M A Wilkerson; D R Clawson
Journal:  J Biol Chem       Date:  1984-03-25       Impact factor: 5.157

3.  Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis.

Authors:  E Handman; G F Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

4.  Leishmania donovani-macrophage binding mediated by surface glycoproteins/antigens: characterization in vitro by a radioisotopic assay.

Authors:  K P Chang
Journal:  Mol Biochem Parasitol       Date:  1981-11       Impact factor: 1.759

5.  Partial chemical characterization of the carbohydrate moieties in Leishmania adleri glycoconjugates.

Authors:  C B Palatnik; J O Previato; P A Gorin; L Mendonça Previato
Journal:  Mol Biochem Parasitol       Date:  1985-01       Impact factor: 1.759

6.  Evidence that the major surface proteins of three Leishmania species are structurally related.

Authors:  R J Etges; J Bouvier; R Hoffman; C Bordier
Journal:  Mol Biochem Parasitol       Date:  1985-02       Impact factor: 1.759

7.  The involvement of the major surface glycoprotein (gp63) of Leishmania promastigotes in attachment to macrophages.

Authors:  D G Russell; H Wilhelm
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

8.  An amphipathic sulphated glycoconjugate of Leishmania: characterization with monoclonal antibodies.

Authors:  E Handman; C L Greenblatt; J W Goding
Journal:  EMBO J       Date:  1984-10       Impact factor: 11.598

9.  The Leishmania receptor for macrophages is a lipid-containing glycoconjugate.

Authors:  E Handman; J W Goding
Journal:  EMBO J       Date:  1985-02       Impact factor: 11.598

10.  Macrophage complement and lectin-like receptors bind Leishmania in the absence of serum.

Authors:  J M Blackwell; R A Ezekowitz; M B Roberts; J Y Channon; R B Sim; S Gordon
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  12 in total

Review 1.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

2.  Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.

Authors:  Ingrid Aguilar-Be; Renata da Silva Zardo; Edilma Paraguai de Souza; Gulnara Patrícia Borja-Cabrera; Miguel Rosado-Vallado; Mirza Mut-Martin; Maria del Rosario García-Miss; Clarisa Beatriz Palatnik de Sousa; Eric Dumonteil
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

3.  A new approach to the phylogeny of Leishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages.

Authors:  C B Palatnik; J O Previato; L Mendonça-Previato; R Borojevic
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

4.  Comparison of receptors required for entry of Leishmania major amastigotes into macrophages.

Authors:  R A Guy; M Belosevic
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

5.  Biochemical and immunological characterization of exometabolites from an Indian strain of Leishmania donovani promastigotes grown in a chemically defined medium.

Authors:  K Kar; K Mukerji; S Kar; D Sarkar; A Bhattacharya; D K Ghosh
Journal:  Mol Cell Biochem       Date:  1991-12-11       Impact factor: 3.396

6.  FML-ELISA a novel diagnostic method for detection of feline leishmaniasis in two endemic areas of Iran.

Authors:  Faeze Foroughi-Parvar; Bahador Sarkari; Qasem Asgari; Gholamreza Hatam
Journal:  J Parasit Dis       Date:  2020-11-10

Review 7.  Nucleoside Hydrolase NH 36: A Vital Enzyme for the Leishmania Genus in the Development of T-Cell Epitope Cross-Protective Vaccines.

Authors:  Clarisa Beatriz Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561

8.  Vaccines for canine leishmaniasis.

Authors:  Clarisa B Palatnik-de-Sousa
Journal:  Front Immunol       Date:  2012-04-17       Impact factor: 7.561

9.  Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil.

Authors:  G P Borja-Cabrera; F N Santos; F S Bauer; L E Parra; I Menz; A A Morgado; I S Soares; L M M Batista; C B Palatnik-de-Sousa
Journal:  Vaccine       Date:  2008-08-22       Impact factor: 3.641

10.  Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

Authors:  Gulnara Patricia Borja-Cabrera; Amanda Cruz Mendes; Edilma Paraguai de Souza; Lilian Y Hashimoto Okada; Fernando Antonio de A Trivellato; Jarbas Kiyoshi A Kawasaki; Andreia Cerqueira Costa; Alexandre Barbosa Reis; Odair Genaro; Leopoldina Maria Melo Batista; Marcos Palatnik; Clarisa Beatriz Palatnik-de-Sousa
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.